Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 504 participants.
Also called NCT02849080
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 504 participants
- Sponsor
- Registry
-
NCT02849080 -
2015-005593-38
-
- Other papers using this trial's data
- Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial
- Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Austria, Belgium, Brazil, Egypt, Norway, South Korea, Switzerland, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT02849080. Randomized; no masking; primary purpose treatment. Start 2016-09-20 (actual); primary completion 2018-02-28 (actual). Results posted on 2020-02-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.
- Acronym
- PIONEER 7
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- semaglutide
- Intervention (Drug)
- sitagliptin
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct02849080- Content hash
3d855b530c59917bb9c8a0dfe74dec3b58a97b0b1ef57e14b4fa933dc322c20a